Company Description
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by interrogating extrachromosomal DNA.
The company’s lead product candidate is ecDTx, BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers.
It develops BBI-098, a picomolar biochemical inhibition of checkpoint kinase 1 demonstrating central nervous system penetrance in preclinical models.
The company offers ECHO, an ecDNA diagnostic test to detect ecDNA in patient tumor specimen; and Spyglass platform, a platform to identify druggable targets in oncogene amplified cancers.
Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019.
The company was incorporated in 2018 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2018 |
| IPO Date | Mar 28, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 64 |
| CEO | Zachary Hornby |
Contact Details
Address: 9880 Campus Point Drive, Suite 120 San Diego, California 92121 United States | |
| Phone | 858 766 9912 |
| Website | boundlessbio.com |
Stock Details
| Ticker Symbol | BOLD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001782303 |
| CUSIP Number | 10170A100 |
| ISIN Number | US10170A1007 |
| Employer ID | 83-0751369 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Zachary Hornby | Chief Executive Officer, President and Director |
| Dr. Jonathan E. Lim M.D. | Co-Founder and Independent Chairman |
| Dr. Christian Hassig Ph.D. | Chief Scientific Officer |
| David Hinkle | Senior Vice President of Finance and Controller |
| Jessica Oien J.D. | Chief Legal Officer and Corporate Secretary |
| Anthony Pinkerton Ph.D. | Senior Vice President of Drug Discovery |
| Meredith Wesley | Senior Vice President of Talent and Culture |
| Dr. Peter Krein Ph.D. | Senior Vice President of Precision Medicine |
| Amy Berkley Ph.D. | Senior Vice President of Program Team |
| Sara Weymer | Senior Vice President of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 10, 2025 | EFFECT | Notice of Effectiveness |
| Apr 1, 2025 | 8-K | Current Report |
| Apr 1, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 27, 2025 | 10-K | Annual Report |
| Mar 27, 2025 | 8-K | Current Report |
| Jan 23, 2025 | UPLOAD | Filing |
| Dec 12, 2024 | 8-K | Current Report |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Oct 29, 2024 | SC 13D | General statement of acquisition of beneficial ownership |